Fund BasicsSee More
- Fund Family Global X Mgt
- Assets Under Management 156,464,000
- Shares Outstanding, K 6,350
- 60-Month Beta 1.12
- Price/Earnings ttm -419.23
- Annual Dividend & Yield 0.03
- Most Recent Dividend 0.032
- Management Fee 0.50%
|Period||Period Low||Period High||Performance|
| || |
-1.67 (-6.35%)since 01/22/21
| || |
+4.48 (+22.22%)since 11/24/20
| || |
+9.65 (+64.38%)since 02/24/20
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Bayer has made a big bet on gene therapy by announcing the acquisition of U.S. biotech firm Asklepios BioPharmaceutical for as much as $4 billion.
The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.
Genomics ETFs have surged of late; here's why
Last week was cheery for Wall Street, with the S&P 500 and Nasdaq recording their best weekly advancement since July.
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.
SpendEdge is a leading procurement intelligence and strategic sourcing partner for leading Fortune 500 firms and several other companies. The company's latest procurement platform - SpendEdge Insights...
Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
|3rd Resistance Point||26.02|
|2nd Resistance Point||25.54|
|1st Resistance Point||25.09|
|1st Support Level||24.16|
|2nd Support Level||23.68|
|3rd Support Level||23.23|